Director Kalin Katherine Bach purchases 63.4K shares of SLS at $1.59, more than doubling her stake to 104.4K shares, amid -30.1% 52-week underperformance.
Director Kalin Katherine Bach acquired 63,400 shares at $1.59 on 2025-11-19, increasing her holdings by 154.6% to 104,400 shares post-transaction. The purchase price sits 4.4% above current market price of $1.53 and represents an accumulation during a period of significant weakness: the stock is -30.1% from its 52-week high and has declined 21.5% over the past 30 days. Notably, Bach's prior open-market purchase at this same ticker on 2025-05-22 produced a 90-day return of +2.8%, reflecting a well-timed entry. The company remains unprofitable with net income of -$6,791,000.00 in the latest period and revenue of $0.00, providing limited fundamental support for conviction signals. The timing and scale of this transaction relative to recent price weakness warrant monitoring of whether this signals directional confidence or represents a tactical accumulation at depressed levels.
SLS Director Kalin Katherine Bach purchased 20,000 shares at $1.80; holdings doubled to 41,000 shares amid -100.0% revenue decline.
Kalin Katherine Bach, a Director at SELLAS Life Sciences, purchased 20,000 shares at $1.80 on 2025-05-22, increasing her holdings by 95.2% to 41,000 shares. The transaction occurs in a company context marked by severe operational deterioration: latest-quarter revenue stands at $0.00 and annual revenue growth is -100.0%, while the company posted a net loss of $-5.8M over its most recent full fiscal year. The stock has recovered 36.4% over the past 30 days and 38.6% over 90 days from lower levels, trading at $1.76 against a 52-week high of $1.94. The substantial increase in her personal stake at a time of negative fundamentals and revenue collapse warrants investor scrutiny into the basis and timing of this accumulation decision.
